X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    New Delivery Path Brings To Light Efficacy of Immunotherapy

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    New Delivery Path Brings To Light Efficacy of Immunotherapy

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Market Moves

Tycko & Zavareei LLP Scores Appellate Victory on Behalf of APA Membership

Yuvraj_pawp by Yuvraj_pawp
5th September 2014
in Market Moves

Tycko & Zavareei has scored a significant appellate victory on behalf of the membership of the American Psychological Association (“APA”). On September 5, 2014, the United States Court of Appeals for the D.C. Circuit reversed the trial court’s dismissal of a class action complaint alleging improper dues-charging practices by the APA, in Levine et al. v. American Psychological Association and American Psychological Association Practice Organization. The decision was authored by Circuit Judge Sri Srinivasan on behalf of a unanimous panel that also included Circuit Judges Judith Rogers and Thomas Griffith.

 

In their class action complaint, members of the APA—represented by Tycko & Zavareei—alleged that the APA falsely represented to its members (on its annual dues statements and elsewhere) that they were required to pay an annual “practice assessment” for continued APA membership. According to the lawsuit, payment of the assessment was not, in fact, a condition of APA membership. Rather, the APA funneled these funds to its lobbying arm: the American Psychological Association Practice Organization (“APAPO”). The plaintiffs asserted that the APA did this because it did not believe that its members would voluntarily donate sufficient funds to the APAPO to support its lobbying activities; however, it could not mandate payment of funds for lobbying purposes as a condition of membership without jeopardizing its tax-exempt status as a 501(c)(3) charitable organization under the Internal Revenue Code. Thus, the APA allegedly tried to have it both ways: by falsely representing in its communications to its members that payment of the practice assessment was a condition of APA membership to obtain funding for the APAPO, but not making payment of the assessment an official membership requirement to avoid potentially losing its federal tax-exempt status.

 

The D.C. Circuit disagreed with the trial court’s conclusion that the plaintiffs failed to state viable legal claims. Namely, the court reversed the dismissal of claims against the APA for unjust enrichment and also disagreed with the trial court’s conclusion that the plaintiffs could not amend their complaint to state a claim for fraudulent inducement on the grounds that any amendment could be futile. Finally, the D.C. Circuit held that the plaintiffs were free to move for leave to amend their complaint to add a cause of action for negligent misrepresentation.

 

In its decision, the D.C. Circuit held that plaintiffs adequately alleged that the APA “included misleading language on the dues statement in order to deceive plaintiffs into overpaying for APA membership.” In assessing the case, the court observed that “the dues statement contained several indications that payment of the special assessment was a requirement of APA membership.” The court also observed that in light of plaintiffs’ allegations that the APA website did not allow payment of dues without payment of the special assessment, “[a] member who viewed the dues statement in conjunction with the website therefore had even greater reason to believe that payment of the special assessment was a condition of APA membership.” In the face of the APA’s contention that despite the misleading language on the dues statements, plaintiffs should have investigated further before paying what they thought was required, the D.C. Circuit panel disagreed, stating that “plaintiffs reasonably could have concluded that the meaning of the dues statement was clear, such that there was no reason to investigate further.”

 

Lead attorney for the plaintiffs, Hassan Zavareei, explained, “This decision by the DC Circuit establishes the basis for a nationwide class against the APA for its deceptive charges of its own members. We are pleased that the case can now proceed so that we can seek restitution for the thousands of psychologists who were duped into paying hundreds of dollars for controversial lobbying efforts by the APA lobbying entity.” The case will now be remanded to the United States District Court for the District of Columbia for further proceedings. The plaintiffs were also represented by Wexler Wallace, LLP, Miller Law Firm, P.C., Greg Coleman Law PC, and Whitfield Bryson & Mason LLP. In addition, Tycko & Zavareei represents the plaintiff in a related class action, Grossman v. American Psychological Association and American Psychological Association Practice Organization.

SOURCE Tycko & Zavareei LLP

Previous Post

Luye Pharma Acquired 57.98% Stake of Beijing Jialin Pharmaceutical

Next Post

Astellas Receives Notification from FDA of Acceptance of Filing of Isavuconazole NDA for the Treatment of Invasive Aspergillosis and Invasive Mucormycosis

Related Posts

Featured

SVB Collapse And Its Implications On Biotechnology Sector

18th March 2023
Featured

US President Looks To Double The Drugs For Price Negotiation

18th March 2023
$118bn Sales By 2026 Is What Japanese Pharma Can Expect
Featured

$118bn Sales By 2026 Is What Japanese Pharma Can Expect

2nd March 2023
Featured

Bioavailability Enhancement Market Projects CAGR of 11%

28th February 2023
Grünenthal to buy NebidoTM testosterone treatment from Bayer for €500m
Market Moves

Grünenthal to buy NebidoTM testosterone treatment from Bayer for €500m

18th July 2022
Could The Long Deckline In Biotechnology M&A Be Ending
Featured

Could The Long Deckline In Biotechnology M&A Be Ending

16th July 2022
Next Post

Astellas Receives Notification from FDA of Acceptance of Filing of Isavuconazole NDA for the Treatment of Invasive Aspergillosis and Invasive Mucormycosis

Latest News

Drug Development

New Delivery Path Brings To Light Efficacy of Immunotherapy

1st April 2023
Cathay Cargo signs global airline partnership with Tower Cold Chain
Packaging & Logistic

Cathay Cargo signs global airline partnership with Tower Cold Chain

31st March 2023
Quotient Sciences completes integration of drug substance into Translational Pharmaceutics Platform
Facilities & Operation

£277m Funding Set To Benefit UK Life Sciences Manufacturing

31st March 2023
Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In